Prostate Cancer News Today

December 3, 2020December 4, 2020

FDA Approves First PSMA-targeted PET Imaging Agent for Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) as a positron emission tomography or PET imaging agent for men with prostate cancer. The ... Read more

December 1, 2020December 1, 2020

FDA Approves FoundationOne Liquid CDx as Companion Test for Lynparza in mCRPC Patients

Prostate Cancer News Today

The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx to be used as a companion diagnostic test to identify men with metastatic castration-resistant prostate cancer (mCRPC) who ... Read more

November 24, 2020November 24, 2020

PCF Helps Fund 2 Centers of Excellence to Treat Veterans With Prostate Cancer

COVID-19 News, Prostate Cancer News Today

The Prostate Cancer Foundation (PCF) has committed $5 million to support the launch of two new Centers of Excellence that will provide precision medicine treatments to veterans with prostate cancer. ... Read more

November 19, 2020November 19, 2020

Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers

Prostate Cancer News Today

The Puerto Rico Health Insurance Administration (ASES) has signed an agreement with miR Scientific to evaluate the economic and health benefits of using the miR Sentinel PCC4 Assay, also called the ... Read more

November 17, 2020November 17, 2020

AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA

COVID-19 News, Prostate Cancer News Today

An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has been granted 501(k) clearance by the U.S. Food and Drug ... Read more

November 12, 2020November 12, 2020

UK Study to Assess Causes of Greater Prostate Cancer Risk Among Black Men

COVID-19 News, Prostate Cancer News Today

Enrollment has resumed in a five-year U.K. study investigating genetic factors behind the higher risk of prostate cancer in men of African and Caribbean descent. The study involves researchers at ... Read more

November 10, 2020November 10, 2020

European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations

Prostate Cancer News Today

The European Commission has approved Lynparza (olaparib) to treat people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in the DNA repair genes BRCA1 and BRCA2. The approval follows a positive ... Read more

November 5, 2020November 5, 2020

Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC

Prostate Cancer News Today

A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, after its clinical hold was lifted. The U.S. Food ... Read more

November 3, 2020November 3, 2020

CAR T-Cell Therapy, MB-105, Shows Promise in Metastatic CRPC Patient in Phase 1 Trial

Prostate Cancer News Today

A heavily pretreated patient with metastatic castration-resistant prostate cancer (mCRPC) showed significant benefits, including a 94% decrease in the levels of the prostate-specific antigen (PSA) biomarker, one month after receiving MB-105 ... Read more

October 29, 2020October 29, 2020

FDA Clears Ezra Prostate AI, a First for Cancer Imaging

Prostate Cancer News Today

The U.S. Food and Drug Administration (FDA) has cleared Ezra Prostate AI, an artificial intelligence (AI) program designed to increase the efficiency with which radiologists analyze images of the prostate ... Read more

October 27, 2020October 27, 2020

New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study

Prostate Cancer News Today

A trial opened to investigate CFI-400945, by Treadwell Therapeutics, as a potential oral therapy for people with metastatic castration-resistant prostate cancer (mCRPC), the company announced in a press release. It is one of ... Read more

October 22, 2020October 22, 2020

ADT Not Needed With Radiation in Favorable Intermediate-Risk PC

Prostate Cancer News Today

Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a Phase ... Read more

October 20, 2020October 20, 2020

Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds

Prostate Cancer News Today

Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at any ... Read more

October 15, 2020October 15, 2020

Trial to Test Focal Laser Ablation Therapy for Localized Prostate Cancer

Prostate Cancer News Today

An investigator-initiated trial soon will evaluate Clinical Laserthermia Systems’ Tranberg Thermal therapy, a focal ablation therapy, for the treatment of prostate cancer patients who have up to medium-grade, localized tumors. ... Read more

October 13, 2020October 13, 2020

New AI Algorithm Can Accurately Identify, Grade Prostate Cancer

Prostate Cancer News Today

A new artificial intelligence (AI) algorithm has been developed that can accurately detect and grade prostate cancer, using slide images from patient core needle prostate biopsies, a study reports. The ... Read more